Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate cancer (mHSPC).
The agency on Monday approved Talzenna in combination with Xtandi, Pfizer’s blockbuster androgen receptor pathway inhibitor (ARPI), for patients with mHSPC whose tumors harbor homologous recombination repair (HRR) gene mutations.
mHSPC is an advanced form of prostate cancer that has spread beyond the prostate but still responds to androgen deprivation therapy. Roughly one in four patients with mHSPC have HRR mutations, which are associated with a poorer prognosis. Even with existing treatments, 50% to 65% of patients with mHSPC progress to metastatic castration-resistant prostate cancer (mCRPC) within two years, according to Pfizer.
The Talzenna-Xtandi combination was previously approved only for HRR-mutated mCRPC, an indication it gained in 2023. The latest approval moves the combination into an earlier treatment setting, expanding its reach to patients whose disease is still hormone-sensitive.
“This approval represents a critical advancement for patients with newly diagnosed metastatic prostate cancer with HRR gene mutations, who face a more aggressive disease, worse prognosis, and limited treatment options,” said Neeraj Agarwal, M.D., co-director of the Prostate Cancer Program at Harvard Cancer Consortium and global lead investigator for TALAPRO-3, the phase 3 trial that supported the FDA decision.
Pfizer’s chief U.S. commercial officer, Aamir Malik, added that the move into an earlier treatment setting offers patients “a new option at a stage where it may have a greater impact to delay progression.”
In the TALAPRO-3 trial, combining Talzenna and Xtandi reduced the risk of radiographic progression or death by 52% in patients with HRR-mutated mHSPC compared with placebo plus Xtandi. The result surpassed Pfizer’s prespecified target of a 37% reduction in the risk of radiographic progression or death.
At the initial readout, Pfizer also noted a “strong trend” toward improved overall survival. However, the FDA said overall survival data for the combination remain immature.
On the safety front, 51% of patients receiving Talzenna plus Xtandi experienced grade 3 or higher anemia, compared with 3% in the control group, according to Pfizer.
The approval offers fresh momentum for Pfizer’s duo after an attempt to expand Talzenna beyond HRR-mutated cancers fell flat in mid-2025. An FDA advisory committee voted unanimously against expanding the Talzenna-Xtandi combination to patients with mCRPC regardless of HRR mutation status, a move that would have opened treatment to a substantially larger population. FDA officials criticized the trial’s “suboptimal design” and questioned the evidence supporting treatment of a “huge number of patients.”
Analysts at RBC Capital Markets previously said the expansion into mHSPC would likely have a “negligible” impact on Pfizer’s bottom line. Talzenna brought in $107 million in the first half of 2026, up 25% year over year but still a small contributor to Pfizer’s oncology portfolio. Nonetheless, the approval is a “win for patients,” the analysts wrote.